Skip to content Skip to footer

News

Latest news from CHV and our portfolio companies 

Featured News

AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems, announced today that it has entered into a financing of up to $75 million. The…

Insights & Impacts: The latest from CHV

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health

Brixton Biosciences, a clinical-stage life sciences company developing novel therapies for chronic and acute pain,

The round was led by SPRIG Equity with participation from all major Series C investors

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital

Data to be presented on February 3rd during a Spotlight Session at AF Symposium 2023

Novel Foam-Based Design Demonstrates Successful LAAO Seal with No Device-Related Thrombus Conformal Medical, Inc., a

Rejoni announced today that it has closed a $25 million Series B financing. The round

– Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse

AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular

Interested in learning more?